At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 105 enrolled
Drug / intervention
Paclitaxeldrug
Likely dose
Carboplatin AUC 5 every 3 weeks for 4 cycles, then paclitaxel 80 mg/m² weekly for 12 infusionsAI-extracted
Key inclusion· 7
- ✓Primary ovarian cancer (FIGO IA/G3–IV)
- ✓ECOG performance status 0–2
- ✓Age ≥18 years
- ✓No prior chemotherapy, radiation, or immunotherapy for ovarian cancer
Key exclusion· 4
- ✕Prior cardiac infarction within 6 months
- ✕Pre-existing heart disease
- ✕Radiotherapy within 4 weeks of study entry
- ✕Pregnancy or breast feeding
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Carboplatin With Following Taxol® Therapy Under Additional Application of Epoetin Alfa (ERYPO ®) With Female Patients With Advanced Ovarian Cancer FIGO IA/G3 - IV
North Eastern German Society of Gynaecological Oncology·interventional·Posted Sep 12, 2005·Updated Feb 6, 2017
In Brief
A Phase 2 clinical trial evaluating Paclitaxel for Ovarian Cancer. Completed, enrolled 105 participants.
Detailed Summary
Time to progression (physical examination and radiologic imaging
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2003
First PostedSep 2005
Primary CompletionApr 2008
Study CompletionJun 2008
TodayJul 2026
First PostedSep 12, 2005
Enrollment StartJul 1, 2003
Primary CompletionApr 1, 2008
Study CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 20.8 years ago
Interventions
Paclitaxeldrug
4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®